Search

Your search keyword '"Moretto R"' showing total 198 results
Start Over Author "Moretto R"
198 results on '"Moretto R"'

1. Predicting early recurrence after resection of initially unresectable colorectal liver metastases: the role of baseline and pre-surgery clinical, radiological and molecular factors in a real-life multicentre experience

Author

Moretto, R., Germani, M.M., Borelli, B., Conca, V., Rossini, D., Boraschi, P., Donati, F., Urbani, L., Lonardi, S., Bergamo, F., Cerma, K., Ramondo, G., D’Amico, F.E., Salvatore, L., Valente, G., Barbaro, B., Giuliante, F., Di Maio, M., Masi, G., and Cremolini, C.

Published
2024
Full Text
View/download PDF

2. Encorafenib plus cetuximab with or without binimetinib in patients with BRAF V600E-mutated metastatic colorectal cancer: real-life data from an Italian multicenter experience

Author

Boccaccino, A., Borelli, B., Intini, R., Antista, M., Bensi, M., Rossini, D., Passardi, A., Tamberi, S., Giampieri, R., Antonuzzo, L., Noto, L., Roviello, G., Zichi, C., Salati, M., Puccini, A., Noto, C., Parisi, A., Rihawi, K., Persano, M., Crespi, V., Libertini, M., Giordano, M., Moretto, R., Lonardi, S., and Cremolini, C.

Published
2022
Full Text
View/download PDF

3. Impact of age and gender on the safety and efficacy of chemotherapy plus bevacizumab in metastatic colorectal cancer: a pooled analysis of TRIBE and TRIBE2 studies

Author

Marmorino, F., Rossini, D., Lonardi, S., Moretto, R., Zucchelli, G., Aprile, G., Dell’Aquila, E., Ratti, M., Bergamo, F., Masi, G., Urbano, F., Ronzoni, M., Libertini, M., Borelli, B., Randon, G., Buonadonna, A., Allegrini, G., Pella, N., Ricci, V., Boccaccino, A., Latiano, T.P., Cordio, S., Passardi, A., Tamburini, E., Boni, L., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

4. Temozolomide and irinotecan (TEMIRI regimen) as salvage treatment of irinotecan-sensitive advanced colorectal cancer patients bearing MGMT methylation

Author

Morano, F., Corallo, S., Niger, M., Barault, L., Milione, M., Berenato, R., Moretto, R., Randon, G., Antista, M., Belfiore, A., Raimondi, A., Nichetti, F., Martinetti, A., Battaglia, L., Perrone, F., Pruneri, G., Falcone, A., Di Bartolomeo, M., de Braud, F., Di Nicolantonio, F., Cremolini, C., and Pietrantonio, F.

Published
2018
Full Text
View/download PDF

5. Primary tumor sidedness and benefit from FOLFOXIRI plus bevacizumab as initial therapy for metastatic colorectal cancer. Retrospective analysis of the TRIBE trial by GONO

Author

Cremolini, C., Antoniotti, C., Lonardi, S., Bergamo, F., Cortesi, E., Tomasello, G., Moretto, R., Ronzoni, M., Racca, P., Loupakis, F., Zaniboni, A., Tonini, G., Buonadonna, A., Marmorino, F., Allegrini, G., Granetto, C., Masi, G., Zagonel, V., Sensi, E., Fontanini, G., Boni, L., and Falcone, A.

Published
2018
Full Text
View/download PDF

7. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest

Author

Cremolini, Chiara, Casagrande, Mariaelena, Loupakis, Fotios, Aprile, Giuseppe, Bergamo, Francesca, Masi, Gianluca, Moretto R, Roberto, Pietrantonio, Filippo, Marmorino, Federica, Zucchelli, Gemma, Tomasello, Gianluca, Tonini, Giuseppe, Allegrini, Giacomo, Granetto, Cristina, Ferrari, Laura, Urbani, Lucio, Cillo, Umberto, Pilati, Pierluigi, Sensi, Elisa, Pellegrinelli, Alessio, Milione, Massimo, Fontanini, Gabriella, and Falcone, Alfredo

Published
2017
Full Text
View/download PDF

10. 341P Trop2 and Nectin4 immunohistochemical expression in metastatic colorectal cancer: An exploratory analysis of the TRIBE2 study

Author

Conca, V., primary, Germani, M.M., additional, Moretto, R., additional, Giordano, M., additional, Bergamo, F., additional, Prisciandaro, M., additional, Antoniotti, C., additional, Ugolini, C., additional, Santini, D., additional, Cupini, S., additional, Boccaccino, A., additional, Barsotti, G., additional, Pagani, F., additional, Niccoli, C., additional, Zaniboni, A., additional, Passardi, A., additional, Tamburini, E., additional, Latiano, T.P., additional, Fontanini, G., additional, and Cremolini, C., additional

Published
2022
Full Text
View/download PDF

11. O-6 Modified FOLFOXIRI plus panitumumab (mFOLFOXIRI/PAN) versus mFOLFOX6/PAN as initial treatment of unresectable RAS/BRAF wild-type metastatic colorectal cancer (mCRC) patients: Results of the phase III randomized TRIPLETE study by GONO

Author

Rossini, D., primary, Antoniotti, C., additional, Lonardi, S., additional, Pietrantonio, F., additional, Marmorino, F., additional, Antonuzzo, L., additional, Boccaccino, A., additional, Randon, G., additional, Giommoni, E., additional, Pozzo, C., additional, Moretto, R., additional, De Grandis, M., additional, Viola, M., additional, Passardi, A., additional, Borelli, B., additional, Buonadonna, A., additional, Masi, G., additional, Formica, V., additional, Aprile, G., additional, Boni, L., additional, and Cremolini, C., additional

Published
2022
Full Text
View/download PDF

14. PD-009 Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Author

Casagrande, M., Moretto, R., Loupakis, F., Cremolini, C., Masi, G., Borelli, B., Lonardi, S., Marsico Valentina, A., Salvatore, L., Rossini, D., Ferrari, L., Ricci, V., Grande, R., Tomasello, G., Ronzoni, M., Allegrini, G., Tonini, G., Mancini, M., Zaniboni, A., Chiara, S., Carlomagno, C., and Falcone, A.

Published
2016
Full Text
View/download PDF

15. O-011 Modified FOLFOXIRI (mFOLFOXIRI) plus cetuximab (cet), followed by cet or bevacizumab (bev) maintenance, in RAS/BRAF wt metastatic colorectal cancer (mCRC): results of the phase II randomized MACBETH trial by GONO

Author

Antoniotti, C., Cremolini, C., Loupakis, F., Bergamo, F., Grande, R., Tonini, G., Garattini Silvio, K., Masi, G., Battaglin, F., Lucchesi, S., Salvatore, L., Corsi, D., Di Fabio, F., Banzi, M., Moretto, R., Sensi, E., Rossini, D., Tomcikova, D., Fontanini, G., Zagonel, V., Boni, L., and Falcone, A.

Published
2016
Full Text
View/download PDF

16. SO-20 Prospective validation of Ang-2 and Tie-2 plasma levels as predictors of benefit from regorafenib in metastatic colorectal cancer patients: REGOLAND study

Author

Antoniotti, C., primary, Marmorino, F., additional, Boccaccino, A., additional, Antista, M., additional, Zaffaroni, N., additional, Zucchelli, G., additional, Martinetti, A., additional, Campi, E., additional, Rossini, D., additional, Sottotetti, E., additional, Borelli, B., additional, Corti, F., additional, Conca, V., additional, Moretto, R., additional, Germani, M., additional, Falcone, A., additional, Giordano, M., additional, Masi, G., additional, Pietrantonio, F., additional, and Cremolini, C., additional

Published
2021
Full Text
View/download PDF

17. A validated prognostic classifier for V600EBRAF-mutated metastatic colorectal cancer: the ‘BRAF BeCool’ study

Author

Loupakis F., Intini R., Cremolini C., Orlandi A., Sartore-Bianchi A., Pietrantonio F., Pella N., Spallanzani A., Dell'Aquila E., Scartozzi M., De Luca E., Rimassa L., Formica V., Leone F., Calvetti L., Aprile G., Antonuzzo L., Urbano F., Prenen H., Negri F., Di Donato S., Buonandi P., Tomasello G., Avallone A., Zustovich F., Moretto R., Antoniotti C., Salvatore L., Calegari M. A., Siena S., Morano F., Ongaro E., Cascinu S., Santini D., Ziranu P., Schirripa M., Buggin F., Prete A. A., Depetris I., Biason P., Lonardi S., Zagonel V., Fassan M., Di Maio M., Loupakis, F., Intini, R., Cremolini, C., Orlandi, A., Sartore-Bianchi, A., Pietrantonio, F., Pella, N., Spallanzani, A., Dell'Aquila, E., Scartozzi, M., De Luca, E., Rimassa, L., Formica, V., Leone, F., Calvetti, L., Aprile, G., Antonuzzo, L., Urbano, F., Prenen, H., Negri, F., Di Donato, S., Buonandi, P., Tomasello, G., Avallone, A., Zustovich, F., Moretto, R., Antoniotti, C., Salvatore, L., Calegari, M. A., Siena, S., Morano, F., Ongaro, E., Cascinu, S., Santini, D., Ziranu, P., Schirripa, M., Buggin, F., Prete, A. A., Depetris, I., Biason, P., Lonardi, S., Zagonel, V., Fassan, M., and Di Maio, M.

Subjects
Adult, Male, Proto-Oncogene Proteins B-raf, Scoring system, DNA Mutational Analysis, Metastases, V600E, BRAF, Colorectal cancer, Prognostic markers, Risk Assessment, Young Adult, Predictive Value of Tests, Risk Factors, Biomarkers, Tumor, Humans, Genetic Predisposition to Disease, Neoplasm Metastasis, Aged, Retrospective Studies, Aged, 80 and over, Middle Aged, Prognosis, Phenotype, Italy, Mutation, Female, Colorectal Neoplasms
Abstract

Background: Despite the well-known negative prognostic value of the V600EBRAF mutation in patients with metastatic colorectal cancer (mCRC), its outcome is quite heterogeneous, and the basis for this prognostic heterogeneity should be better defined. Methods: Two large retrospective series of V600EBRAF-mutated mCRC from 22 institutions served as an exploratory and validation set to develop a prognostic score. The model was internally and externally validated. Results: A total of 395 V600EBRAF-mutated mCRCs were included in the exploratory set. Performance status, CA19.9, lactate dehydrogenase, neutrophil/lymphocyte ratio, grading and liver, lung and nodal involvement emerged as independent prognostic factors for overall survival (OS). Two different scoring systems were built: a ‘complete’ score (0–16) including all significant covariates and a ‘simplified’ score (0–9), based only on clinicopathological covariates, and excluding laboratory values. Adopting the complete score, proportions of patients with a low (0–4), intermediate (5–8) and high (9–16) score were 44.7%, 42.6% and 12.6%, respectively. The median OS was 29.6, 15.5 (hazard ratio [HR] for intermediate vs low risk: 2.16, 95% confidence interval [CI]: 1.44–3.22, p < .001) and 6.6 months (HR for high vs low risk: 4.72, 95% CI: 2.72–8.20, p < .001). Similar results were observed also after adjusting for the type of first-line treatment and adopting the simplified score. The simplified prognostic score derived from the exploratory set was then applied to the validation set for external confirmation. Conclusions: These scoring systems are based on easy-to-collect data and defined specific subgroups with relevant differences in their life expectancy. These tools could be useful in clinical practice, would allow better stratification of patients in clinical trials and may be adopted for proper adjustments in exploratory translational analyses.

Published
2019

18. SO-32 Predictive impact of RNF43 mutation (mut) in pMMR/MSS BRAFV600E-mutated metastatic colorectal cancer (mCRC) patients (pts) treated with target therapy (TT) or chemotherapy (CT)

Author

Germani, M., Moretto, R., Ros, J., Intini, R., Ghelardi, F., Vetere, G., Toledo, R., Bergamo, F., Randon, G., Elez, E., Lonardi, S., Oldani, S., Giordano, M., Rossini, D., Bravo, W. Ferrari, Ricagno, G., Vignali, P., Ugolini, C., Fontanini, G., and Cremolini, C.

Published
2023
Full Text
View/download PDF

19. SO-28 FOLFOXIRI plus bevacizumab and atezolizumab as upfront treatment of unresectable mCRC patients: Updated and overall survival results of the phase II randomized AtezoTRIBE study

Author

Antoniotti, C., Rossini, D., Pietrantonio, F., Salvatore, L., Marmorino, F., Ambrosini, M., Lonardi, S., Bensi, M., Moretto, R., Tamberi, S., Toma, I., Passardi, A., De Grandis, M., Conca, V., Palermo, M., Cappetta, A., Catteau, A., Boni, L., Galon, J., and Cremolini, C.

Published
2023
Full Text
View/download PDF

21. O-18 Tumor mutational load, microsatellite instability, BRCAness, and actionable alterations in metastatic colorectal cancer: Results from the TRIBE2 study

Author

Antoniotti, C., primary, Rossini, D., additional, Marmorino, F., additional, Lonardi, S., additional, Corti, F., additional, Moretto, R., additional, Ugolini, C., additional, Latiano, T., additional, Giordano, M., additional, Tamburini, E., additional, Passardi, A., additional, Santini, D., additional, Zaniboni, A., additional, Aprile, G., additional, Bordonaro, R., additional, Zucchelli, G., additional, Conca, V., additional, Fontanini, G., additional, Lenz, H., additional, Falcone, A., additional, Korn, M., additional, and Cremolini, C., additional

Published
2020
Full Text
View/download PDF

23. PIK3CA mutation in metastatic colorectal cancer (mCRC): Association with clinico-pathological features and outcome

Author

Fanotto, V., primary, Zucchelli, G., additional, Germani, M.M., additional, Rossini, D., additional, Sensi, E., additional, Lupi, C., additional, Ugolini, C., additional, Antoniotti, C., additional, Marmorino, F., additional, Moretto, R., additional, Boccaccino, A., additional, Borelli, B., additional, Conca, V., additional, Ongaro, E., additional, Masi, G., additional, Fontanini, G., additional, Falcone, A., additional, and Cremolini, C., additional

Published
2019
Full Text
View/download PDF

24. Evaluation of safety, immunogenicity and preliminary efficacy of PolyPEPI1018 vaccine in subjects with metastatic colorectal cancer (mCRC) with a predictive biomarker

Author

Hubbard, J., primary, Cremolini, C., additional, Graham, R.P., additional, Moretto, R., additional, Mitchell, J., additional, Wessling, J., additional, Tőke, E.R., additional, Csiszovszki, Z., additional, Lorincz, O., additional, Molnar, L., additional, Somogyi, E., additional, Megyesi, M., additional, Pántya, K., additional, Toth, J., additional, Pales, P., additional, Miklos, I., additional, and Falcone, A., additional

Published
2019
Full Text
View/download PDF

25. Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO

Author

Rossini, D., primary, Lonardi, S., additional, Antoniotti, C., additional, Santini, D., additional, Tomasello, G., additional, Aprile, G., additional, Moretto, R., additional, Prete, A.A., additional, Granetto, C., additional, Urbano, F., additional, Borelli, B., additional, Zaniboni, A., additional, Randon, G., additional, Buonadonna, A., additional, Ritorto, G., additional, Barbara, C., additional, Latiano, T.P., additional, Bordonaro, R., additional, Falcone, A., additional, and Cremolini, C., additional

Published
2019
Full Text
View/download PDF

26. Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis

Author

Rossini, D., primary, Pagani, F., additional, Pellino, A., additional, Dell’Aquila, E., additional, Liscia, N., additional, Bensi, M., additional, Germani, M., additional, Masi, G., additional, Moretto, R., additional, Santini, D., additional, Salvatore, L., additional, Scartozzi, M., additional, Lonardi, S., additional, Zucchelli, G., additional, Puglisi, F., additional, Vannini, F., additional, Colombo, C., additional, Falcone, A., additional, Pietrantonio, F., additional, and Cremolini, C., additional

Published
2019
Full Text
View/download PDF

27. Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

Author

Rossini, D., primary, Sbrana, A., additional, Bergamo, F., additional, Manai, C., additional, Santini, D., additional, Ghidini, M., additional, Antoniotti, C., additional, Moretto, R., additional, Marmorino, F., additional, Urbano, F., additional, Ronzoni, M., additional, Noventa, S., additional, Randon, G., additional, Carlomagno, C., additional, Latiano, T., additional, Cordio, S., additional, Granetto, C., additional, Cremolini, C., additional, Falcone, A., additional, and Antonuzzo, A., additional

Published
2019
Full Text
View/download PDF

28. Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

Author

Zucchelli, G., primary, Marmorino, F., additional, Rossini, D., additional, Aprile, G., additional, Casagrande, M., additional, Lonardi, S., additional, Murgioni, S., additional, Dell’Aquila, E., additional, Tomasello, G., additional, Moretto, R., additional, Antoniotti, C., additional, Borelli, B., additional, Urbano, F., additional, Ronzoni, M., additional, Zaniboni, A., additional, Manglaviti, S., additional, Buonadonna, A., additional, Ritorto, G., additional, Masi, G., additional, Allegrini, G., additional, Falcone, A., additional, and Cremolini, C., additional

Published
2019
Full Text
View/download PDF

29. Molecular characterization of immune microenvironment in colorectal cancers with microsatellite instability by digital RNA counting

Author

Giordano, M., primary, Moretto, R., additional, Giannini, R., additional, Zucchelli, G., additional, Pietrantonio, F., additional, Antoniotti, C., additional, Ugolini, C., additional, Morano, F., additional, Marmorino, F., additional, Sensi, E., additional, Belfiore, A., additional, Rossini, D., additional, Lupi, C., additional, Masi, G., additional, Borelli, B., additional, Ongaro, E., additional, Boccaccino, A., additional, Falcone, A., additional, Cremolini, C., additional, and Fontanini, G., additional

Published
2018
Full Text
View/download PDF

30. Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)

Author

Ongaro, E., primary, Rossini, D., additional, Pietrantonio, F., additional, Morano, F., additional, de Braud, F., additional, Mazzaferro, V., additional, Corti, F., additional, Randon, G., additional, Raimondi, A., additional, Battaglia, L., additional, Morelli, L., additional, Urbani, L., additional, Masi, G., additional, Moretto, R., additional, Antoniotti, C., additional, Marmorino, F., additional, Borelli, B., additional, Zucchelli, G., additional, Boccaccino, A., additional, Cremolini, C., additional, and Falcone, A., additional

Published
2018
Full Text
View/download PDF

31. Efficacy of FOLFOXIRI plus bevacizumab in liver-limited metastatic colorectal cancer: A pooled analysis of clinical studies by Gruppo Oncologico del Nord Ovest

Author

Roberto Moretto R, Gianluca Masi, Gabriella Fontanini, Cristina Granetto, Giuseppe Tonini, Umberto Cillo, Giuseppe Aprile, Giacomo Allegrini, Fotios Loupakis, Alfredo Falcone, Gianluca Tomasello, Laura Ferrari, Lucio Urbani, Massimo Milione, Francesca Bergamo, Mariaelena Casagrande, Elisa Sensi, Chiara Cremolini, Alessio Pellegrinelli, Pierluigi Pilati, Federica Marmorino, Gemma Zucchelli, and Filippo Pietrantonio

Subjects
0301 basic medicine, Oncology, Adult, Male, Cancer Research, medicine.medical_specialty, Bevacizumab, Organoplatinum Compounds, Colorectal cancer, Leucovorin, Angiogenesis Inhibitors, Disease, Kaplan-Meier Estimate, Disease-Free Survival, Liver metastases, 03 medical and health sciences, Young Adult, FOLFOXIRI, Metastatic colorectal cancer, 0302 clinical medicine, Internal medicine, Antineoplastic Combined Chemotherapy Protocols, medicine, Humans, Prospective Studies, Aged, Medical treatment, business.industry, Liver Neoplasms, Middle Aged, medicine.disease, Clinical trial, Regimen, 030104 developmental biology, Pooled analysis, 030220 oncology & carcinogenesis, Multivariate Analysis, Camptothecin, Female, Fluorouracil, business, Colorectal Neoplasms, medicine.drug
Abstract

Secondary resection is a chance of cure for a subgroup of metastatic colorectal cancer (mCRC) patients with unresectable liver-limited disease. Medical treatment has a dual goal: to induce tumour shrinkage and to prevent disease relapse. The aims of the present analysis were to assess the efficacy of FOLFOXIRI plus bevacizumab in this setting, and to investigate whether this regimen could revert the poor prognosis of high-risk patients defined by clinical and molecular factors. We performed a pooled analysis of patients with unresectable and liver-limited mCRC, treated with first-line FOLFOXIRI plus bevacizumab in three prospective clinical trials by Gruppo Oncologico del Nord Ovest. 205 (37.9%) patients with liver-limited disease were selected, out of 541 treated patients. Liver metastases were synchronous, ≥4 and bilobar in 90%, 61%, and 79% of cases, respectively. The largest diameter was5 cm in 42% of cases, and ≥6 segments were involved in 25%. Seventy-four patients (36.1%) underwent R0 or R1 resection of metastases. R2 resections were performed in 17 cases (8.3%). Having6 involved segments (p 0.001) and achieving RECIST response (p = 0.019) were associated with higher chances of resection. R0/R1 resected patients had significantly longer median progression-free survival (PFS) (18.1 versus 10.7 months, HR: 0.48 [0.35-0.66], p 0.001) and overall survival (OS) (44.3 versus 24.4 months, HR: 0.32 [0.22-0.48], p 0.001) compared with other patients, both in the univariate and multivariate analyses (PFS p = 0.025; OS p 0.001). The 5-year PFS and OS rate in R0 resected patients were 12% and 43%, respectively. Neither negative baseline characteristics nor high clinical risk scores or RAS/BRAF mutations were associated with poor post-resection outcomes. In conclusion, FOLFOXIRI plus bevacizumab demonstrates efficacy in the conversion setting with considerable long-term outcome results independent of clinical and molecular prognostic factors (NCT00719797, NCT01163396 and NCT02271464).

Published
2016

32. STATO DELL'ARTE SULLA CHEMIOTERAPIA NEL CANCRO DEL COLON

Author

Moretto R, DE STEFANO, ALFONSO, CARLOMAGNO, Chiara, Moretto, R, DE STEFANO, Alfonso, and Carlomagno, Chiara

Subjects
chemioterapia, tumori del colon-retto, Farmaci a bersaglio Molecolare
Abstract

Il trattamento del tumore del colon ha subito notevoli cambiamenti negli ultimi anni. Se, infatti, la terapia adiuvante continua a basarsi su fluoropirimidine +/- oxaliplatino, la terapia per la malattia metastatica, in aggiunta ai classici agenti chemioterapici, si avvale oggi di farmaci a bersaglio molecolare (anti-VEGF, anti-EGFR e inibitori multichinasici) che hanno portato a sopravvivenze medie di circa due anni. Quale sia la migliore combinazione tra ???vecchi??? e ???nuovi??? farmaci, la migliore sequenza e l???integrazione con la chirurgia delle metastasi è ancora oggetto di discussione. In questo capitolo ci si propone di presentare una panoramica della terapia del tumore del colon.

Published
2014

33. FOLFOXIRI or FOLFOXIRI plus bevacizumab as first-line treatment of metastatic colorectal cancer: a propensity score-adjusted analysis from two randomized clinical trials.ANNALS OF ONCOLOGY, ISSN: 0923-7534

Author

Cremolini, C, Loupakis, F, Masi, G, Lonardi, S, Granetto, C, Mancini, Marialaura, Chiara, S, Moretto, R, Rossini, Daniela, Vitello, S, Allegrini, G, Tonini, G, Bergamo, F, Tomasello, G, Ronzoni, M, Buonadonna, A, Bustreo, S, Barbara, C, Boni, Maria Luisa, and Falcone, A. 1. 5.

Published
2016

34. Circulating angiogenesis-related markers as predictors of benefit from regorafenib in metastatic colorectal cancer (mCRC) patients (pts)

Author

Antoniotti, C., primary, Marmorino, F., additional, Pennati, M., additional, Zaffaroni, N., additional, Rossini, D., additional, Borelli, B., additional, Zucchelli, G., additional, Moretto, R., additional, Pietrantonio, F., additional, Masi, G., additional, Vannini, F., additional, Colombo, C., additional, Saettini, A., additional, Gini, S., additional, Delliponti, L., additional, Pfanner, E., additional, Brunetti, I., additional, Falcone, A., additional, and Cremolini, C., additional

Published
2017
Full Text
View/download PDF

35. Dissecting primary resistance to anti-EGFRs in RAS and BRAF wt metastatic colorectal cancer (mCRC): A case-control study

Author

Rossini, D., primary, Cremolini, C., additional, Morano, F., additional, Berenato, R., additional, Tamborini, E., additional, Perrone, F., additional, Moretto, R., additional, Gloghini, A., additional, Busico, A., additional, Zucchelli, G., additional, Baratelli, C., additional, Tamburini, E., additional, Fucà, G., additional, Volpi, C., additional, Milione, M., additional, Di Maio, M., additional, Fontanini, G., additional, de Braud, F., additional, Falcone, A., additional, and Pietrantonio, F., additional

Published
2017
Full Text
View/download PDF

38. 570P - Treatments (tx) after progression to first-line FOLFOXIRI + bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts): A pooled analysis of TRIBE and TRIBE-2 studies by GONO

Author

Rossini, D., Lonardi, S., Antoniotti, C., Santini, D., Tomasello, G., Aprile, G., Moretto, R., Prete, A.A., Granetto, C., Urbano, F., Borelli, B., Zaniboni, A., Randon, G., Buonadonna, A., Ritorto, G., Barbara, C., Latiano, T.P., Bordonaro, R., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

39. PD-027 - Efficacy of retreatment with anti-EGFRs in metastatic colorectal cancer is not predictable by clinical factors related to prior lines of therapy: a multi-institutional analysis

Author

Rossini, D., Pagani, F., Pellino, A., Dell’Aquila, E., Liscia, N., Bensi, M., Germani, M., Masi, G., Moretto, R., Santini, D., Salvatore, L., Scartozzi, M., Lonardi, S., Zucchelli, G., Puglisi, F., Vannini, F., Colombo, C., Falcone, A., Pietrantonio, F., and Cremolini, C.

Published
2019
Full Text
View/download PDF

40. PD-015 - Clinical impact of neutropenia and febrile neutropenia in metastatic colorectal cancer patients treated with FOLFOXIRI/bevacizumab: a pooled analysis of TRIBE and TRIBE2 studies

Author

Rossini, D., Sbrana, A., Bergamo, F., Manai, C., Santini, D., Ghidini, M., Antoniotti, C., Moretto, R., Marmorino, F., Urbano, F., Ronzoni, M., Noventa, S., Randon, G., Carlomagno, C., Latiano, T., Cordio, S., Granetto, C., Cremolini, C., Falcone, A., and Antonuzzo, A.

Published
2019
Full Text
View/download PDF

41. O-013 - Impact of age and gender on safety and efficacy of first-line FOLFOXIRI/bevacizumab in mCRC: a pooled analysis of TRIBE and TRIBE2 studies

Author

Zucchelli, G., Marmorino, F., Rossini, D., Aprile, G., Casagrande, M., Lonardi, S., Murgioni, S., Dell’Aquila, E., Tomasello, G., Moretto, R., Antoniotti, C., Borelli, B., Urbano, F., Ronzoni, M., Zaniboni, A., Manglaviti, S., Buonadonna, A., Ritorto, G., Masi, G., Allegrini, G., Falcone, A., and Cremolini, C.

Published
2019
Full Text
View/download PDF

42. Lactate dehydrogenase (LDH) levels predict benefit from the continuation of bevacizumab (bev) beyond progression in metastatic colorectal cancer (mCRC): subgroup analysis of the randomized BEBYP study

Author

Marmorino, F., primary, Cremolini, C., additional, Loupakis, F., additional, Salvatore, L., additional, Masi, G., additional, Barbara, C., additional, Dargenio, F., additional, Miraglio, E., additional, Ginocchi, L., additional, Antonuzzo, L., additional, Moretto, R., additional, Schirripa, M., additional, Chiara, S., additional, Banzi, C., additional, Amoroso, D., additional, Bonetti, A., additional, Martignetti, A., additional, Paris, M., additional, Boni, L., additional, Tomcikova, D., additional, and Falcone, A., additional

Published
2016
Full Text
View/download PDF

43. Safety and efficacy of FOLFOXIRI with or without targeted agents as first-line treatment of selected elderly metastatic colorectal cancer patients: a pooled analysis of GONO studies

Author

Rossini, D., primary, Casagrande, M., additional, Moretto, R., additional, Loupakis, F., additional, Cremolini, C., additional, Masi, G., additional, Borelli, B., additional, Lonardi, S., additional, Zagonel, V., additional, Aprile, G., additional, Ricci, V., additional, Grande, R., additional, Tomasello, G., additional, Ronzoni, M., additional, Allegrini, G., additional, Tonini, G., additional, Mancini, M.L., additional, Zaniboni, A., additional, Chiara, S., additional, Carlomagno, C., additional, and Falcone, A., additional

Published
2016
Full Text
View/download PDF

45. PD-017 - Clinical and molecular determinants of extrahepatic disease progression (ePD) in initially unresectable, liver-limited metastatic colorectal cancer (mCRC)

Author

Ongaro, E., Rossini, D., Pietrantonio, F., Morano, F., de Braud, F., Mazzaferro, V., Corti, F., Randon, G., Raimondi, A., Battaglia, L., Morelli, L., Urbani, L., Masi, G., Moretto, R., Antoniotti, C., Marmorino, F., Borelli, B., Zucchelli, G., Boccaccino, A., Cremolini, C., and Falcone, A.

Published
2018
Full Text
View/download PDF

47. Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib

Author

Antoniotti, C., primary, Loupakis, F., additional, Schirripa, M., additional, Cremolini, C., additional, Poliseno, L., additional, Salvatore, L., additional, Tuccoli, A., additional, D'Aurizio, R., additional, Marmorino, F., additional, Borelli, B., additional, Rossini, D., additional, Saettini, A., additional, Gini, S., additional, Moretto, R., additional, Rizzo, I., additional, Dell'Aquila, E., additional, Pellegrini, M., additional, and Falcone, A., additional

Published
2015
Full Text
View/download PDF

48. P-198 Circulating microRNAs in metastatic colorectal cancer (mCRC) patients (pts) treated with regorafenib

Author

Schirripa, M., primary, Loupakis, F., additional, Cremolini, C., additional, Poliseno, L., additional, Salvatore, L., additional, Tuccoli, A., additional, Antoniotti, C., additional, D'Aurzio, R., additional, Marmorino, F., additional, Borelli, B., additional, Rossini, D., additional, Saettini, A., additional, Gini, S., additional, Moretto, R., additional, Rizzo, I., additional, Dell' Aquila, E., additional, Pellegrini, M., additional, and Falcone, A., additional

Published
2015
Full Text
View/download PDF

Catalog

Books, media, physical & digital resources
See catalog results